Overview

Corporate Profile

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.



Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.20
Change (%) Stock is Down 0.04 (0.76%)
Volume56,872
Data as of 12/09/16 1:58 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
11/11/16T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
LEXINGTON, Mass., Nov. 11, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17, 2016, at 2:00 p.m. ET in New York City. A live, listen-only webcast of the presentation may be accessed by visiting the Investors/Events & Presentations sect... 
Printer Friendly Version
11/03/16T2 Biosystems Announces New Data at IDWeek 2016
Data Demonstrates Clinical and Economic Benefits of T2 Magnetic Resonance (T2MR®) Technology in Clinical Settings LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that the Company’s T2Candida® Panel for rapid sepsis detection and T2 Magnetic Resonance (T2MR®) technology for detecting early-stage Lyme disease were the focus of several poster presentations during ... 
Printer Friendly Version
11/01/16T2 Biosystems Reports Third Quarter Results
Recent Collaborations and Strategic Investment Position Company for Long-Term Growth Company to Track Number of High-Risk Patients as Key Reporting Metric Company Refocusing Resources Ahead of T2BacteriaÔ Launch LEXINGTON, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced results for the third quarter ended September 30, 2016. Recent Operational and Third Quarter Perfo... 
Printer Friendly Version
11/01/16T2 Biosystems Announces Collaboration with Allergan to Develop the First Blood-Based Diagnostic Panel to Detect Antimicrobial Resistance
-- T2 Biosystems to develop new panel on T2Dx platform and commercialize worldwide while receiving milestone and other payments – -- Panel to aid in rapid bacterial infection diagnosis, including sepsis; enable quicker treatment with life-saving medicines for millions of patients – -- Allergan granted option to co-market suite of diagnostic products in targeted hospitals -- LEXINGTON, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovat... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646
Data provided by Nasdaq. Minimum 15 minutes delayed.